Inclusion Criteria:  Adults 18 years of age at the time of screening or >= 40 years and presenting at least one comorbidity : high blood pressure; a known obesity and/ or a known and treated diabete. COVID-19 confirmed by molecular biology a viral syndrome with or without uncomplicated pneumonia, defined as blood oxygen saturation level (SpO2) >=94%. Mild Covid-19 symptoms with an onset < 7 days before inclusion. Signed written consent from the patient or his/her representative. No need an oxygen therapy according to international guidelines (WHO Progression Scale, grade 2 to 4) Accepting and having the ability to be reached by telephone throughout the study. Having designated a contact person who can be contacted in case of emergency. Accepted to be reached by phone along throughout the study  Exclusion Criteria:  Blood oxygen saturation level (SpO2) < 94%. Known hypersensitivity to investigational products On-going treatment with Telmisartan Chronic treatment with inhaled corticosteroids (up to 30 days) Renal or hepatic failure or known history of renal or hepatic failure  Abnormal physical examination findings:  respiratory rate < 25 per minute; blood pressure < 90/60 mmHg or > 160/100 mmHg; Feeling unwell for more than 7 days prior to screening. End-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months. For any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. Unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the Investigator or cannot use an inhalation chamber. Any other reason that makes it impossible to monitor the patient during the study.